Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6856 to 6870 of 8904 results

  1. Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]

    Discontinued Reference number: GID-TA10322

    Technology appraisal guidance
    Discontinued

  2. Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353

    Discontinued Reference number: GID-TA10320

    Technology appraisal guidance
    Discontinued

  3. Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]

    Discontinued Reference number: GID-TA10271

    Technology appraisal guidance
    Discontinued

  4. Guadecitabine for untreated acute myeloid leukaemia [ID1411]

    Discontinued Reference number: GID-TA10325

    Technology appraisal guidance
    Discontinued

  5. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]

    In development Reference number: GID-TA10858 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]

    Discontinued Reference number: GID-TA10452

    Technology appraisal guidance
    Discontinued

  7. Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]

    In development Reference number: GID-TA11645 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer [ID6472]

    In development Reference number: GID-TA11589 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475]

    In development Reference number: GID-TA11586 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]

    In development Reference number: GID-TA11299 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Glaucoma - lerdelimumab (CAT-152) [ID383]

    Discontinued Reference number: GID-TAG381

    Technology appraisal guidance
    Discontinued

  12. Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]

    Discontinued Reference number: GID-TA11411

    Technology appraisal guidance
    Discontinued

  13. Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]

    In development Reference number: GID-TA11365 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]

    In development Reference number: GID-TA11709 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]

    In development Reference number: GID-TA11689 Expected publication date: TBC

    Technology appraisal guidance
    In development